¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"growth rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • growth hormone-releasing hormone
    ¼ºÀåÈ£¸£¸ó¹æÃâÈ£¸£¸ó
  • growth inducer
    ¼ºÀåÀ¯¹ßÀÎÀÚ
  • growth line
    ¼ºÀå¼±
  • growth pattern
    ¼ºÀå¾ç½Ä
  • growth period
    ¼ºÀå±â°£
  • growth phase
    Áõ½Ä±â
  • growth plate
    ¼ºÀåÆÇ
  • growth quotient
    ¼ºÀåÁö¼ö, ¹ßÀ°Áö¼ö
  • growth recovery line
    ¼ºÀåȸº¹¼±
  • growth regulator
    ¼ºÀåÁ¶ÀýÀÎÀÚ
  • growth retardation
    ¹ßÀ°Áö¿¬, ¼ºÀåÁö¿¬
  • growth spurt
    ¼ºÀå±ÞÁõ
  • growth zone
    ¼ºÀ屸¿ª, ¼ºÀå´ë
  • growth-onset diabetes
    ¹ßÀ°±â¹ßº´´ç´¢º´, Ãʱâ´ç´¢º´
  • hematopoietic growth factor
    Ç÷¾×Çü¼º¼ºÀåÀÎÀÚ, Á¶Ç÷¼ºÀåÀÎÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • five-year survival rate
    ¿À³â»ýÁ¸·ü
  • glomerular filtration rate
    Å丮¿©°úÀ², »ç±¸Ã¼¿©°úÀ²
  • heart rate
    ½ÉÀå¹Úµ¿¼ö
  • infant mortality rate
    ¿µ¾Æ»ç¸Á·ü
  • morbidity rate
    ÀÌȯ·ü
  • mortality rate
    »ç¸Á·ü
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • onset rate
    ¹ß»ý·ü
  • operative mortality rate
    ¼ö¼ú»ç¸Á·ü
  • peak expiratory flow rate
    ÃÖ°í³¯¼û¼Óµµ, ÃÖ°íÈ£±âÀ¯¼Ó
  • perfusion rate
    °ü·ù¼Óµµ, °ü·ùÀ²
  • pregnancy rate
    Àӽŷü
  • prevalence rate
    À¯º´·ü
  • pulse rate
    ¸Æ¹Ú¼ö
  • relaxation rate
    À̿Ϸü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • macrophage-derived growth factor
    Å«Æ÷½Ä¼¼Æ÷À¯·¡¼ºÀåÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • growth
    ¼ºÀå, Áõ½Ä
  • growth hormone
    ¼ºÀåÈ£¸£¸ó
  • growth inducer
    ¼ºÀåÀ¯¹ßÀÎÀÚ
  • growth line
    ¼ºÀå¼±
  • growth pattern
    ¼ºÀå¾ç½Ä
  • growth period
    ¼ºÀå±â°£
  • growth phase
    Áõ½Ä±â
  • growth plate
    (¢¡epiphyseal cartilage) »À³¡¿¬°ñ
  • growth quotient
    ¼ºÀåÁö¼ö, ¹ßÀ°Áö¼ö
  • growth regulator
    ¼ºÀåÁ¶ÀýÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • heat transfer rate
    ¿­Àü´Þ·ü(ÊÙËô).
  • hebdomadal death rate
    »ýÈÄÀÏÁÖ°£»ç¸Á·ü(ÊÙË×ËÎËô).
  • high dose rate
    °í¼±·®À²
  • high dose rate intraluminal radiotherapy
    °í¼±·®À² °ü³»¹æ»ç¼±Ä¡·á
  • incidence rate
    ¹ßº´·ü, ½Åȯ¹ß»ý·ü
  • incidence rate
    ¹ß»ý·ü(ËÑË×Ëô).
  • infant mortality rate
    ¿µ¾Æ»ç¸Á·ü.
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü(úìíìôÑá¼ã÷ëÒ).
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À².
  • postneonatal mortality rate
    ÈĽŻý¾Æ»ç¸Á·ü(Ì·ËàË×ËâË×ËÎËô).
  • pregnancy rate
    ÀÓ½ÅÀ²(ìôããëÒ).
  • prevalence [rate]
    À¯º´·ü
  • prevalence rate
    À¯º´·ü(ËôËÓËô).
  • production rate
    »ý»êÀ²
  • puerperal death rate
    »ê¿å»ç¸Á·ü (ÊÙË×ËÎËô).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • epidermal growth factor
    Ç¥ÇǼºÀå ÀÎÀÚ(¡­à÷íþ ì×í­)
  • epidermal growth factor (EGF)
    ÇǺÎÁõ½ÄÀÎÀÚ
  • epidermal growth factor = EGF
    Ç¥ÇÇ ¼ºÀå ÀÎÀÚ
  • epidermoid growth factor
    Ç¥ÇÇ¾ç ¼ºÀåÀÎÀÚ(¡­à÷íþì×í­)
  • essential growth factor
    ÇʼöÁõ½ÄÀÎÀÚ
  • excessive growth
    ¼ºÀå°úµµ
  • exponential growth
    Áö¼öÁõ½Ä.
  • exponential growth phase
    Áö¼öÁõ½Ä±â(ÊÙÌ¡ËàË»).
  • exponential phase of growth
    ´ë¼öÁõ½Ä±â, °¡¼Ó¼ºÀå±â.
  • face growth
  • fetal growth retardation
    ÅÂ¾Æ ¹ßÀ° Áö¿¬, ÅÂ¾Æ ¼ºÀå Áö¿¬
  • fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷ ¼ºÀåÀÎÀÚ(¡­à÷íþì×í­)
  • fibroblast growth factor(FGF)
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀåÀÎÀÚ
  • grain growth
    ÀÔÀÚÀÇ ¼ºÀå.
  • growth
    ¼ºÀå, Áõ½Ä
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • growth hormone release-inhibiting hormone
    ¼ºÀå(à÷íþ) È£¸£¸ó ¹æÃâÀúÇØ (Û¯õóîÁúª) È£¸£¸ó
  • growth hormone releasing hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó ¹æÃâ (Û¯õó)È£¸£¸ó
  • growth medium
    ¼ºÀå¹èÁö (à÷íþÛÆò¢)
  • growth retardant
    ¼ºÀåÁö¿¬Á¦(à÷íþòÀæÅð¥)
  • head growth
    ¸Ó¸®¼ºÀå (à÷íþ)
  • headward growth
    ¸Ó¸®ÂÊ ¼ºÀå(à÷íþ)
  • linear growth
    ¼±Çü¼ºÀå(àÊû¡à÷íþ)
  • logarithmic growth
    ´ë¼ö Áõ½Ä(ÓÛâ¦ñòãÖ)
  • molar growth yield
    ¸ô¼ºÀå¼öÀ²(à÷íþâ¥ëÏ)
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ(ãêÌèà÷íþì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡(úìá³÷ùë¦ÕÎ) ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • step-growth polymer
    ´Ü°è¼ºÀå ÁßÇÕü(Ó«Í­à÷íþñìùêô÷)
  • synchronous growth
    µ¿±â¼ºÀå (ÔÒÑ¢à÷íþ)
  • tail growth
    ²¿¸®¼ºÀå (à÷íþ)
  • tailward growth
    ²¿¸®¹æÇâ ¼ºÀå (à÷íþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MR Maddox rods; magnetic resistance; magnetic resonance; mandibular reflex; mannose-resistant; may repe...
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
IDA   1) Imino-Diacetic Acid
  2) Iron Deficiency Anemia
   &nb...
GD gastroduodenal; Gaucher disease; general diagnostics; general dispensary; gestational day; Gianotti ...
GF gastric fistula; gastric fluid; germ-free; glass factor; glomerular filtration; gluten-free; grandfa...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AR Attack Rate
ADMR Average daily metabolic rate
BMR Basal Metabolic Rate
BFR Blood flow rate
BFR Bone formation rate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • total growth
    ÃÑ Áõ½Ä·®
  • tumor growth
    Á¾¾ç ¼ºÀå
  • uncontrolled destructive growth
    ºñÁ¶Àý¼º ÆÄ±«¼º ¼ºÀå
    ÀÎÀ§ÀûÀ¸·Î Á¶ÀÛÀÌ ¾ÈµÇ°í ÀÚ¶ó¸é¼­ ÆÄ±«Àû ¼ºÁúÀ» Áö´Ï´Â °Í.
  • vascular endothelial growth factor
    ¸Æ°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ, Ç÷°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ
  • vertical growth
    ¼öÁ÷ ¼ºÀå
  • absorptace rate
    Èí¼öÀ²
    ÀÎü¿¡ Á¶»çµÇ´Â ¹æ»ç¼±¿¡ ´ëÇØ ÀÎü¿¡ Èí¼öµÇ´Â ¹æ»ç¼± ¿¡³ÊÁöÀÇ ºñÀ².
  • absorption rate
    Èí¼öÀ²
    ÀÏÁ¤ ½Ã°£¿¡ »¡¾ÆµéÀÌ´Â ¼Óµµ¸¦ ³ªÅ¸³»´Â À².
  • adjusted death rate
    Á¶Á¤ »ç¸Á·ü
  • attack rate
    ¹ßº´·ü, ÀÌȯÀ²
  • basal metabolic rate
    ±âÃÊ ´ë»çÀ²
    ½Ä»ç ÈÄ ÀÏÁ¤ ½Ã°£ÀÌ Áö³ª°í ³ª¼­ÀÇ ¾ÈÁ¤ »óÅ¿¡¼­ÀÇ »ê¼Ò ¼Òºñ ¼Óµµ.
  • cardiac rate
    ½É¹Ú ¼ö
    µ¿ÀǾî=heart rate.
  • caries incidence rate
    ¿ì½Ä¹ß»ýÀ²
    ÀÏÁ¤ÇÑ ±â°£¿¡ ¹ß»ýÇÏ´Â ¿ì½Ä ¹ß»ýÀ², ¨ç Æò±Õ ³â°£ ¿ì½Ä¹ß»ýÀ² =
  • case fatality rate
    Ä¡¸í·ü
  • conversion rate
    ÀüȯÀ²
  • D.E.F. rate
    µð.ÀÌ.¿¡ÇÁ
    Decayed Extractlion, FilledÀÇ ¾àÀÚ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
rate setting and review A method of examining and setting levels of payments.
(12 Dec 1998)
general fertility rate A refined measure of fertility in a population; the numerator is the number of live births in a year, the denominator is the number of females of child-bearing age, usually defined as ages 15-44 (but increasingly recognised as extending to age 49).
(05 Mar 2000)
recurrence rate In genetic counseling, the risk that a future offspring will be affected given some specific set of relatives of whom at least one is already affected.
(05 Mar 2000)
case fatality rate The proportion of individuals contracting a disease that die of that disease.
(05 Mar 2000)
maternal death rate The number of maternal deaths that occur as the direct result of the reproductive process per 100,000 live births.
See: rate.
See: maternal death.
(05 Mar 2000)
maternal mortality rate The number of maternal deaths related to childbearing divided by the number of live births (or by the number of live births + foetal deaths) in that year. The maternal mortality rate in the united states in 1993 (and 1994) was 0.1 per 1,000 live births, or 1 mother dying per 10,000 live births.
(12 Dec 1998)
maximal expiratory flow rate <chest medicine, physiology> Measurement of rate of airflow during the first liter expired after the first 200 ml have been exhausted during a forced vital capacity determination. Common abbreviations are MEFR, FEF 202-1200, and fef 0.2-1.2.
Acronym: MEFR
(21 Jun 2000)
maximal midexpiratory flow rate Measurement of rate of airflow over the middle half of a forced vital capacity determination (from the 25 percent level to the 75 percent level). Common abbreviations are mmfr and fef 25%-75%.
(12 Dec 1998)
glomerular filtration rate <nephrology> Measure of the kidneys' ability to filter and remove waste products.
(09 Oct 1997)
peak expiratory flow rate Measurement of the maximum rate of airflow attained during a forced vital capacity determination. Common abbreviations are pefr and pfr.
(12 Dec 1998)
peak flow rate Maximum urinary flow rate during voiding as measured by a uroflowmeter.
(05 Mar 2000)
repetition rate The number of pulses per minute, describing an energy outpute.g., ultrasound pulses in echocardiography rather than vascular pulses.
(05 Mar 2000)
voiding flow rate Urinary flow as a function of time during micturition, as graphically recorded by a flow meter.
(05 Mar 2000)
volume loading rate The rate of raw materials put into a fermenter or aerobic digester, expressed in terms of material weight per unit volume per unit time.
(09 Oct 1997)
respiration rate Frequency of breathing, recorded as the number of breaths per minute.
(05 Mar 2000)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
growth rate Growth in Sales or Revenue
Ãâó: www.intrinsicvalue.com/glossary.htm
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • discount rate
    ¾îÀ½ ÇÒÀÎÀ²;ÀçÇÒÀÎÀ²
  • effective exchange rate
    (±ÝÀ¶)½ÇÈ¿ ȯ½Ã¼¼(ȯÀ²)(±¹Á¦ÅëÈ­±â±ÝÀÌ ´çÇØ±¹°ú ´Ù¸¥ ÁÖ¿ä 20°³±¹ ÅëÈ­ÀÇ È¯½Ã¼¼¸¦ º¹ÇÕ½ÃÄÑ »êÃâÇÏ´Â Áö¼ö)
  • exchange rate
    ȯÀ²
  • fatality rate
    »ç¸Á·ü
  • fixed exchange rate(system)
    °íÁ¤È¯½Ã¼¼(Á¦)
  • flat rate
    °íÁ¤(Á¤¾×)¿ä±Ý
  • floating exchange rate system
    º¯µ¿ ȯÀ²Á¦
  • floating rate
    ÀÚÀ¯ º¯µ¿ ½Ã¼¼;¼±Çϼ¼
  • forward rate
    (¿Ü±¹È¯ÀÇ) ¼±¹° ½Ã¼¼
  • freight rate
    ¿îÀÓ·ü Àå
  • fuel rate
    Ãʰ£ ¿¬·á ¼ÒºñÀ²
  • interest rate
    ±Ý¸®ÀÌÀ²
  • kill rate
    (ÀüÀï,Æøµ¿ µîÀÇ)»ì»ý·ü 9
  • milline rate
    1milline ´çÀÇ ±¤°í·á
  • minimum lending rate
    (¿µ)(À×±Û·£µå ÀºÇàÀÇ) ÃÖÀú ´ëÃ⠱ݸ®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á